Physician profile

Zuhair Yahya

San Dimas, CA

NPI 1477514057

$451.61

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$208.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $112.25 2019-2023 Trulicity, Mounjaro
Novo Nordisk INC $100.87 2022-2023 Rybelsus, Ozempic
Abbott Laboratories $51.27 2019-2023 Freestyle Libre 3
Astrazeneca Pharmaceuticals LP $42.58 2023 Farxiga
E.R. Squibb & Sons, L.L.C. $38.69 2021-2022
Horizon Therapeutics Plc $27.05 2022
Abbvie INC. $25.41 2023 Synthroid
Janssen Pharmaceuticals, INC $23.59 2019
Insulet Corporation $17.20 2023 Omnipod
Dexcom, INC. $12.70 2023 Dexcom G6 Transmitter

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Zuhair Yahya

$451.61

in general payments reported 2019-2025

Years
2019-2023
Top company
Lilly USA, LLC

https://glasscript.com/doctor/1300057/zuhair-yahya

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.